Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

NCT04072445 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Advanced Bile Duct Carcinoma
Advanced Gallbladder Carcinoma
Refractory Bile Duct Carcinoma
Refractory Gallbladder Carcinoma
Stage III Distal Bile Duct Cancer AJCC v8
Stage III Gallbladder Cancer AJCC v8
Stage III Intrahepatic Bile Duct Cancer AJCC v8
Stage IIIA Distal Bile Duct Cancer AJCC v8
Stage IIIA Gallbladder Cancer AJCC v8
Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8
Stage IIIB Distal Bile Duct Cancer AJCC v8
Stage IIIB Gallbladder Cancer AJCC v8
Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8
Stage IV Distal Bile Duct Cancer AJCC v8
Stage IV Gallbladder Cancer AJCC v8
Stage IV Intrahepatic Bile Duct Cancer AJCC v8
Stage IVA Gallbladder Cancer AJCC v8
Stage IVB Gallbladder Cancer AJCC v8

Interventions

DRUG: Irinotecan
DRUG: Irinotecan Hydrochloride
DRUG: Trifluridine and Tipiracil Hydrochloride

Sponsor

Mayo Clinic

Collaborators

[object Object]